Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Eliquis
Eliquis 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-124386 · Präparat HOS-095863
Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel
75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in
Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of
platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases
in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 7f13a0d795fea8f1700acb8c491ed9ae122183b0de5847671e52fd5ca3ec5565 · Zeichen 3277–3761 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 45
HOS-124441 · Präparat HOS-095863
Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel
75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in
Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of
platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases
in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 7f13a0d795fea8f1700acb8c491ed9ae122183b0de5847671e52fd5ca3ec5565 · Zeichen 3205–3689 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 0.15 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 75
HOS-124493 · Präparat HOS-095863
Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel
75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in
Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of
platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases
in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 7f13a0d795fea8f1700acb8c491ed9ae122183b0de5847671e52fd5ca3ec5565 · Zeichen 3489–3973 im Abschnitt
Wechselwirkungen · Eliquis
Eliquis 0.5 mg coated granule in sachet Eliquis 1.5 mg coated granules in sachet Eliquis 2 mg coated granules in sachet · Abschnitt 4.5 · PDF-Seite 98
HOS-124544 · Präparat HOS-095863
Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel
75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in
Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of
platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases
in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T16:18:00Z · SHA-256 2c0830820630062f4840bfa3480c75f2e906f4d88046edf420c3e31195b50b2d · Passage 7f13a0d795fea8f1700acb8c491ed9ae122183b0de5847671e52fd5ca3ec5565 · Zeichen 3500–3984 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-134015 · Präparat HOS-097520
Co-administration of clopidogrel
with cobicistat is expected to
decrease clopidogrel active
metabolite plasma concentrations,
which may reduce the antiplatelet
activity of clopidogrel.
Prasugrel Interaction not studied with any of No dose adjustment of prasugrel is
the components of Genvoya. required.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage fd0733069f777fda9fce8834c5e50773cef3ede57c85a04bde543e7b462ef6be · Zeichen 37677–38236 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-134017 · Präparat HOS-097520
Genvoya is not expected to have a
clinically relevant effect on plasma
concentrations of the active
metabolite of prasugrel.
INHALED BETA AGONIST
Salmeterol Interaction not studied with any of Concurrent administration of
the components of Genvoya. salmeterol and Genvoya is not
recommended.
Co-administration with Genvoya
may result in increased plasma
concentrations of salmeterol, which
is associated with the potential for
serious or life-threatening adverse
reactions.
HMG CO-A REDUCTASE INHIBITORS
Rosuvastatin (10 mg single dose)/ Elvitegravir: Concentrations of rosuvastatin are
Elvitegravir (150 mg once daily)/ AUC: ↔ transiently increased when
Cobicistat (150 mg once daily) Cmin: ↔ administered with elvitegravir and
Cmax: ↔ cobicistat. Dose modifications are
not necessary when rosuvastatin is
Rosuvastatin: administered in combination with
AUC: ↑ 38% Genvoya.
Cmin: N/A
Cmax: ↑ 89%
Atorvastatin (10 mg single Atorvastatin: Concentrations of atorvastatin are
dose)/Elvitegravir (150 mg once AUC: ↑ 160% increased when co-administered
daily)/Cobicistat (150 mg once Cmin: N/A with elvitegravir and cobicistat.
daily)/Emtricitabine (200 mg once Cmax: ↑ 132% Start with the lowest possible dose
daily)/Tenofovir alafenamide of atorvastatin with careful
(10 mg once daily) Elvitegravir: monitoring upon co-administration
AUC: ↔ with Genvoya.
Cmin: ↔
Cmax: ↔
Pitavastatin Interaction not studied with any of Caution should be exercised when
the components of Genvoya. co-administering Genvoya with
pitavastatin.
Concentrations of pitavastatin may
be increased when administered
with elvitegravir and cobicistat.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) rosuvastatin (HOS-086307) salmeterol (HOS-086285) prasugrel (HOS-112066) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 7e31f3eeee923ea18ba80fdd3f8b3ff8a1b59702bd502d3e1a8df30b4a2beea0 · Zeichen 38274–41404 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 14
HOS-134492 · Präparat HOS-097580
Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel
clopidogrel with boosted darunavir is with boosted darunavir is not
expected to decrease clopidogrel active recommended.
metabolite plasma concentration,
which may reduce the antiplatelet Use of other antiplatelets not
activity of clopidogrel. affected by CYP inhibition or
induction (e.g. prasugrel) is
recommended.
Warfarin Not studied. Warfarin concentrations It is recommended that the
may be affected when co-administered international normalised ratio (INR)
with darunavir with low dose ritonavir. be monitored when warfarin is
combined with darunavir co-
administered with low dose
ritonavir.
ANTICONVULSANTS
Phenobarbital Not studied. Phenobarbital and Darunavir co-administered with low
Phenytoin phenytoin are expected to decrease dose ritonavir should not be used in
plasma concentrations of darunavir and combination with these medicines.
its pharmacoenhancer.
(induction of CYP450 enzymes)
Carbamazepine carbamazepine AUC ↑ 45% No dose adjustment for
200 mg twice daily carbamazepine Cmin ↑ 54% darunavir/ritonavir is
carbamazepine Cmax ↑ 43% recommended. If there is a need to
darunavir AUC ↔ combine darunavir/ritonavir and
darunavir Cmin ↓ 15% carbamazepine, patients should be
darunavir Cmax ↔ monitored for potential
carbamazepine-related adverse
events. Carbamazepine
concentrations should be monitored
and its dose should be titrated for
adequate response.
Based upon the findings, the
carbamazepine dose may need to be
reduced by 25% to 50% in the
presence of darunavir/ritonavir.
Clonazepam Not studied. Co-administration of Clinical monitoring is
boosted darunavir with clonazepam recommended when co-
may increase concentrations of administering boosted darunavir
clonazepam. (CYP3A inhibition) with clonazepam.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) clonazepam (HOS-116372) clopidogrel (HOS-087927) prasugrel (HOS-112066) ritonavir (HOS-084521) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 18f88a1538e549d8b6880998a637a7940712c9de8be51f9feea7646da83d20c9 · Zeichen 26132–29743 im Abschnitt
Wechselwirkungen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55
HOS-134615 · Präparat HOS-097580
Ticagrelor Based on theoretical considerations, Concomitant administration of
co-administration of boosted boosted darunavir with ticagrelor is
darunavir with ticagrelor may contraindicated (see section 4.3).
increase concentrations of ticagrelor
(CYP3A and/or P-glycoprotein
inhibition).
Clopidogrel Not studied. Co-administration of Co-administration of clopidogrel
clopidogrel with boosted darunavir with boosted darunavir is not
is expected to decrease clopidogrel recommended.
active metabolite plasma
concentration, which may reduce Use of other antiplatelets not affected
the antiplatelet activity of by CYP inhibition or induction (e.g.
clopidogrel. prasugrel) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) clopidogrel (HOS-087927) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 7a02cfd41eefb91b52e416ead5113ab1097c212830ee09000ecd6aecda42a6a8 · Zeichen 31318–32428 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138482 · Präparat HOS-098200
Clopidogrel Based on theoretical Co-administration of Symtuza
considerations co-administration of with clopidogrel is not
Symtuza with clopidogrel is recommended. Use of other
expected to decrease clopidogrel antiplatelets not affected by CYP
active metabolite plasma inhibition or induction (e.g.
concentration, which may reduce prasugrel) is recommended (see
the antiplatelet activity of section 4.3).
clopidogrel.
Warfarin Based on theoretical It is recommended that the
considerations DRV/COBI may international normalised ratio
alter warfarin plasma (INR) be monitored when
concentrations. warfarin is co-administered with
Symtuza.
ANTICONVULSANTS
Carbamazepine Based on theoretical Co-administration of Symtuza
Phenobarbital considerations these and these anticonvulsants is
Phenytoin anticonvulsants are expected to contraindicated (see section 4.3).
decrease darunavir and/or
cobicistat and/or tenofovir
alafenamide plasma
concentrations.
(CYP3A and/or P-gp induction).
Oxcarbazepine Co-administration of Symtuza
with oxcarbazepine is not
recommended. Alternative
anticonvulsants should be
considered.
Clonazepam Based on theoretical considerations Clinical monitoring is
Symtuza is expected to increase recommended when
concentrations of clonazepam. co-administering Symtuza with
(inhibition of CYP3A) clonazepam.
ANTI-DEPRESSANTS
Herbal supplements Based on theoretical considerations Co-administration of
St. John’s Wort St. John’s Wort is expected to St. John’s Wort and Symtuza is
decrease darunavir and/or contraindicated (see section 4.3).
cobicistat and/or tenofovir
alafenamide plasma
concentrations.
(CYP3A and/or P-gp induction)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) phenobarbital (HOS-085617) carbamazepine (HOS-085618) clonazepam (HOS-116372) clopidogrel (HOS-087927) prasugrel (HOS-112066) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 187c0fed160e40c7da0a4ce1c8b126337a2665df943610da374a786680424cda · Zeichen 11857–14725 im Abschnitt
Wechselwirkungen · Apixaban Accord
Apixaban Accord 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-146629 · Präparat HOS-099542
11
Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel
75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in
Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of
platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases
in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T13:45:00Z · SHA-256 d61ca619dbc3cc41b936fd00150a7483792c8b53e4c986c4c86af1cceab6e2ab · Passage dc2a16de4451811ce7f7492d5f9677a73fe32879edb88cf99e1868eea9e18140 · Zeichen 3269–3757 im Abschnitt
Wechselwirkungen · Apixaban Accord
Apixaban Accord 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 44
HOS-146678 · Präparat HOS-099542
Apixaban coadministered with clopidogrel (75 mg once a day) or with the combination of clopidogrel
75 mg and ASA 162 mg once daily, or with prasugrel (60 mg followed by 10 mg once daily) in
Phase I studies did not show a relevant increase in template bleeding time, or further inhibition of
platelet aggregation, compared to administration of the antiplatelet agents without apixaban. Increases
in clotting tests (PT, INR, and aPTT) were consistent with the effects of apixaban alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): clopidogrel (HOS-087927) prasugrel (HOS-112066)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-27T13:45:00Z · SHA-256 d61ca619dbc3cc41b936fd00150a7483792c8b53e4c986c4c86af1cceab6e2ab · Passage 7f13a0d795fea8f1700acb8c491ed9ae122183b0de5847671e52fd5ca3ec5565 · Zeichen 3201–3685 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.